NCT03769207

Brief Summary

This post-marketing study is conducted to characterize the ability of Apple Watch rhythm analysis software to identify Atrial Fibrillation (AF) and facilitate subsequent clinical evaluation among users who contact AppleCare.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
17

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
Completed

Started Dec 2018

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 7, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

December 8, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 5, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 20, 2019

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

October 20, 2020

Completed
Last Updated

October 20, 2020

Status Verified

September 1, 2020

Enrollment Period

7 months

First QC Date

December 6, 2018

Results QC Date

September 25, 2020

Last Update Submit

September 25, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Atrial Fibrillation or Atrial Flutter (AF) of at Least 30 Seconds Duration

    Detected on ambulatory ECG patch monitor for a participant who received an IRN or Apple Watch ECG app - AFib classification

    During ambulatory ECG Monitoring (up to 8 days)

Secondary Outcomes (2)

  • Arrhythmias Other Than AF

    During ambulatory ECG Monitoring (up to 8 days)

  • Self-reported Contact With Healthcare Provider

    Between 15 to 90 days following enrollment

Study Arms (1)

Ambulatory ECG

OTHER
Device: Ambulatory ECG

Interventions

Eligible participants are asked to wear the ambulatory ECG monitor

Ambulatory ECG

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Possession of the following at time of eligibility screening:
  • iPhone (5s or later) with iOS version 12.1.1 or later defined as iPhone model/iOS version used to complete screening eligibility.
  • Apple Watch (Series 1-4) with watchOS version 5.1.2 or later defined as Apple Watch model/watchOS paired with iPhone used to complete screening eligibility
  • At least one of the following by self-report before consent:
  • Irregular Rhythm Notification
  • ECG app classification of Atrial Fibrillation
  • ECG app classification of Inconclusive defined as "Inconclusive," "Heart Rate Over 120," or "Heart Rate Under 50"
  • Age ≥ 22 years at time of eligibility screening
  • Current resident of the United States at time of eligibility screening, and will reside in the United States for the length of the study
  • Proficient in written and spoken English
  • Valid phone number associated with iPhone, ascertained from self-report
  • Valid email address, ascertained from self-report

You may not qualify if:

  • Shared iCloud account
  • Shared AppleWatch

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94304, United States

Location

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, CardiacAtrial Flutter

Interventions

Electrocardiography, Ambulatory

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ElectrocardiographyHeart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosisMonitoring, AmbulatoryMonitoring, Physiologic

Limitations and Caveats

The small number of enrolled participants prevents us from drawing meaningful conclusions from this study.

Results Point of Contact

Title
Marco Perez, Associate Professor of Medicine
Organization
Stanford University

Study Officials

  • Marco V Perez, MD

    Stanford University

    PRINCIPAL INVESTIGATOR
  • Minang (Mintu) Turakhia, MD, MAS

    Stanford University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine (Cardiovascular Medicine)

Study Record Dates

First Submitted

December 6, 2018

First Posted

December 7, 2018

Study Start

December 8, 2018

Primary Completion

July 5, 2019

Study Completion

August 20, 2019

Last Updated

October 20, 2020

Results First Posted

October 20, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations